The FDA approved a fixed-dose combination of carbachol and brimonidine tartrate for presbyopia, offering a noninvasive ...

Combining two eye drops that have been on the market for at least 30 years each has earned Tenpoint Therapeutics an FDA ...

The FDA has approved the first dual-agent eye drop to treat presbyopia, a condition that causes gradual loss of near vision in adults.

Tenpoint Therapeutics’ Yuvezzi brings a combination approach to presbyopia compared to single mechanisms of action offered by once-daily eye drops from Orasis Pharmaceuticals, Lenz Therapeutics, and ...

Yuvezzi, a combination cholinergic agonist and alpha-adrenergic agonist, is now FDA-approved as a once-daily treatment for ...

The FDA approved Yuvezzi, an eye drop for the treatment of presbyopia, with broad U.S. availability expected in the second quarter, according to a press release from Tenpoint Therapeutics. Yuvezzi ...

The biotech also raised $235 million in debt and equity funding to support marketing of the drop, which it claims to be an ...

Tenpoint Therapeutics announced FDA’s approval of Yuvezzi (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1% ...

Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to ...

Once-daily carbachol/brimonidine tartrate significantly improves aging-related vision loss ...

Please provide your email address to receive an email when new articles are posted on . The submission is supported by positive data from the phase 3 BRIO-I and BRIO-II studies. If approved, Brimochol ...